GreenLight Biosciences Holdings, (GRNA) News
Filter GRNA News Items
GRNA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest GRNA News From Around the Web
Below are the latest news stories about GREENLIGHT BIOSCIENCES HOLDINGS PBC that investors may wish to consider to help them evaluate GRNA as an investment opportunity.
GreenLight Biosciences Enters into Definitive Merger Agreement with Consortium Led by Fall Line Endurance Fund for Go-Private TransactionGreenLight Biosciences GreenLight Biosciences Enters into Definitive Merger Agreement with Consortium Led by Fall Line Endurance Fund for Go-Private Transaction LEXINGTON, Mass., May 30, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences Holdings, PBC (NASDAQ: GRNA) (“GreenLight” or the “Company”) today announced that the Company has entered into a definitive agreement (the “Merger Agreement”) to be acquired by a group of buyers led by Fall Line Capital, LLC (“Fall Line”) in an all-cash transaction |
GreenLight Biosciences Announces First Quarter 2023 Financial Results and Highlights Recent Company ProgressImage: GreenLight Biosciences Image: GreenLight Biosciences BOSTON, May 11, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences, PBC (Nasdaq: GRNA), a biotechnology company dedicated to making RNA products affordable and accessible for human health and agriculture, today reported operational highlights and financial results for the first quarter ended March 31, 2023. “GreenLight is sharply focused on its mission, leveraging scientific expertise, global partnerships, and the power of our platform to |
GreenLight Biosciences Releases Inaugural Sustainability ReportGreenLight greenhouse GreenLight is sharing its business strategy and how it can impact food security, biodiversity, health, and climate in its 2022 Sustainability Report. BOSTON, April 12, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to deliver on the full potential of RNA to address some of the world’s toughest problems in human health and agriculture, today released its inaugural Sustainability Report. The report contains the company's |
GreenLight Biosciences Holdings Confirms Receipt of Indication of Interest from Fall LineGreenLight Biosciences Holdings Confirms Receipt of Indication of Interest from Fall Line Image: GreenLight Biosciences BOSTON, March 30, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences (Nasdaq: GRNA) (“GreenLight” or the “Company”), a public benefit corporation striving to deliver on the full potential of RNA to address some of the world’s toughest problems in human health and agriculture, today, confirmed that it has received a non-binding indication of interest from Fall Line Endurance Fund, |
GreenLight Biosciences Announces Fourth Quarter and Full Year 2022 Financial ResultsGreenLight's RTP greenhouse facility in North Carolina GreenLight's RTP greenhouse facility in North Carolina Two agriculture solutions now under regulatory review, pending EPA approval: Calantha™, a solution to protect potatoes, and a separate solution to protect honeybees from Varroa miteUpdated clinical strategy to accelerate development of its next-generation Covid vaccine candidate; decision to advance universal pan-sarbecovirus vaccine candidatePresented promising preclinical immune respon |
GreenLight Biosciences Outlines Development Strategy and Highlights Portfolio Updates at Human Health R&D DayGreenLight human health day image GreenLight today outlines its pipeline strategy and R&D progress for mRNA-based solutions during its Human Health R&D Day -- Progressing human health pipeline conferring mRNA platform advantages for infectious disease and personalized oncology medicines; pursuing capital efficient strategy targeting unmet medical needs, in both the developed and lower- and middle-income countries (LMICs), pairing focused R&D spend with partnerships -- Accelerating development of |
GreenLight Biosciences Outlines Development Strategy and Highlights Portfolio Updates at Plant Health R&D DayGreenLight R&D day GreenLight is actively preparing for commercial launch prior to end of 2023 of our leading dsRNA solution, Calantha™, subject to regulatory approval. BOSTON, March 07, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to deliver on the full potential of RNA to address some of the world’s toughest problems in human health and agriculture, will today outline its pipeline strategy and R&D progress for dsRNA based crop protection |
GreenLight Biosciences to Host R&D Day Series on Plant and Human Health Development StrategyImage: GreenLight Biosciences Lexington lab GreenLight Biosciences today announced it will host a two-part R&D Day Series for analysts and investors. BOSTON, March 01, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to deliver on the full potential of RNA to address some of the world’s toughest problems in human health and agriculture, today announced it will host a two-part R&D Day Series for analysts and investors. Session One: Plant Health |
GreenLight Biosciences receives approval to initiate Phase I/II clinical trial of Covid-19 mRNA vaccine candidateKigali city, as seen from the north Kigali city, as seen from the north The Rwanda FDA has given regulatory approval to GreenLight to start a Phase I/II clinical trial of its Covid-19 vaccine candidate in Rwanda. This phase I/II clinical trial is the first step in GreenLight’s integrated strategy of bringing a universal Covid-19 mRNA vaccine to market globally. By initiating this first-in-human clinical study in Rwanda, GreenLight is demonstrating its commitment to partner with the people of Afr |
GreenLight Biosciences and Epivax Therapeutics Sign Exclusive Collaboration Agreement to Develop Personalized Cancer VaccinesGreenLight GreenLight’s mRNA design, formulation and manufacturing expertise is currently applied to research and develop mRNA vaccine candidates The effort will combine GreenLight’s mRNA design and manufacturing expertise with EpiVax’s advanced Ancer® pipeline for personalized cancer vaccine designEpivax Therapeutics, Inc. will contribute a proprietary set of immunoinformatics tools for rapidly identifying and differentiating highly immunogenic neo-antigens from epitopes that induce immune tole |